CDR-Life Appoints Dimitrios Chondros as Chief Medical Officer

Zürich, Switzerland – February 3, 2026 – CDR-Life, Inc., a clinical-stage biotechnology company focused on developing T cell engagers (TCEs) for cancer and autoimmune diseases, announced the appointment of Dimitrios Chondros, MD, as its Chief Medical Officer (CMO). [1]

Dr. Chondros’ Role and Experience

As CMO, Dr. Chondros will lead CDR-Life’s clinical development, clinical operations, medical affairs, and translational strategy. [2] He brings over 20 years of experience in global drug development, medical leadership, and oncology expertise from both biotechnology and pharmaceutical organizations. [1]

Prior to joining CDR-Life, Dr. Chondros served as Chief Medical Officer for Halozyme. [4] He likewise held the position of Global Development Team Leader for Avastin® in colorectal cancer at Genentech. [1]

CDR-Life’s M-gager® Platform

Dr. Chondros’ appointment comes during a period of progress for CDR-Life as the company advances its proprietary M-gager® platform into clinical-stage programs. [1]

Leadership Perspective

Christian Leisner, PhD, Chief Executive Officer of CDR-Life, stated, “Dimitrios is a highly respected clinical leader with a rare combination of hands-on drug development experience, global leadership perspective and medical expertise.” [1] Leisner added that Dr. Chondros’ leadership will be crucial as CDR-Life progresses its M-gager programs and expands its pipeline in oncology and autoimmune diseases. [3]

Dr. Chondros’ Background

Dr. Chondros is a board-certified general surgeon. [1] He received his medical education at RWTH University Aachen, Germany, and University Zürich, Switzerland. [1]